Wen Kong, Guangyu Wu, Yunze Xu, Zaoyu Wang, Jin Zhang. "Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.5_suppl.443